Creative Planning boosted its position in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 72.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,600 shares of the company’s stock after acquiring an additional 12,000 shares during the quarter. Creative Planning’s holdings in TherapeuticsMD were worth $139,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. We Are One Seven LLC purchased a new stake in TherapeuticsMD in the fourth quarter worth about $26,000. Dfpg Investments Inc. purchased a new stake in TherapeuticsMD in the fourth quarter worth about $38,000. Weiss Multi Strategy Advisers LLC purchased a new stake in TherapeuticsMD in the fourth quarter worth about $57,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in TherapeuticsMD by 26.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,648 shares of the company’s stock worth $67,000 after buying an additional 3,649 shares in the last quarter. Finally, Amalgamated Bank increased its position in TherapeuticsMD by 145.3% in the fourth quarter. Amalgamated Bank now owns 26,314 shares of the company’s stock worth $100,000 after buying an additional 15,586 shares in the last quarter. Institutional investors own 80.03% of the company’s stock.

TXMD has been the subject of a number of analyst reports. Oppenheimer restated a “buy” rating on shares of TherapeuticsMD in a research report on Tuesday, March 19th. BidaskClub upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th. restated a “buy” rating and issued a $14.00 price target on shares of TherapeuticsMD in a research report on Tuesday, February 12th. ValuEngine upgraded TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $27.00 price target on shares of TherapeuticsMD in a research report on Monday, January 21st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $12.75.

NASDAQ TXMD opened at $3.25 on Thursday. The stock has a market capitalization of $796.03 million, a PE ratio of -5.51 and a beta of 1.96. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.39 and a quick ratio of 3.28. TherapeuticsMD Inc has a twelve month low of $3.19 and a twelve month high of $7.66.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The firm had revenue of $3.95 million during the quarter, compared to analyst estimates of $5.96 million. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.11) earnings per share. Equities research analysts predict that TherapeuticsMD Inc will post -0.64 earnings per share for the current fiscal year.

In other news, Director Jules A. Musing sold 17,400 shares of the company’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $5.80, for a total value of $100,920.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at $29,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.85% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Creative Planning Boosts Position in TherapeuticsMD Inc (TXMD)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2019/05/16/creative-planning-boosts-position-in-therapeuticsmd-inc-txmd.html.

TherapeuticsMD Profile

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.